Astrazeneca plcAZN
Price$161.47Intrinsic value$211.1331% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $211.13median of 6 methods · middle span $135-$419based on filings through 31 Dec 2025
Market Price $161.47Price as of 30 Sep 2026
Margin of Safety +30.8%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 14.8% (near-term consensus, capped) · years 2–5: 11.0%/yr (balance of the path).11.8% per year
Years 6–10: glide to demonstrated growth own history 21.8%, capped at 20%
Per-year rates
Yr 611.2%Yr 711.3%Yr 811.5%Yr 911.6%Yr 1011.8%
11.0% → 11.8%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1110.9%Yr 1210.0%Yr 139.1%Yr 148.3%Yr 157.4%Yr 166.5%Yr 175.6%Yr 184.8%Yr 193.9%Yr 203.0%
11.8% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)21.8%
Discount rate (cost of equity) 7.2%
Volatility vs market (adjusted beta)0.51

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetAstrazeneca plcAZNHealth Care
Valuation
P/E—
P/S4.4×
P/B5.3×
EV / Revenue4.7×
EV / EBITDA—
Profitability
Gross margin—
Operating margin23.4%
Net margin17.4%
FCF margin20.0%
Returns
ROE21.0%
ROA9.0%
ROIC15.1%
Growth
Revenue growth (YoY)8.6%
5-yr fwd EPS growth11.8%
Financial strength
Debt / Equity0.51×
Current ratio0.94×
Altman Z-Score—
Interest coverage—
Dividend yield1.3%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.